Cefpodoxime Concentrations in Human Serum and Oral Tissues Following a Single Oral Administration of Cefpodoxime Proxetil

  • Ono Makiko
    Departments of Oral Surgery, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan Resarch Institute of Oral Science, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan
  • Omata Hiroaki
    Departments of Oral Surgery, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan
  • Nishimura Hitoshi
    Departments of Oral Surgery, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan Resarch Institute of Oral Science, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan
  • Tanaka Shigeo
    Departments of Oral Surgery, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan Resarch Institute of Oral Science, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan
  • Matsumoto Hiroko
    Departments of Pharmacology, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan Resarch Institute of Oral Science, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan
  • Fujii Akira
    Professor Emeritus, Nihon University, 4-8-24 Kudan-Minami, Chiyoda, Tokyo 102-8275, Japan
  • Akimoto Yoshiaki
    Departments of Oral Surgery, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan
  • Komiya Masamichi
    Departments of Oral Surgery, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan Resarch Institute of Oral Science, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan

この論文をさがす

抄録

Cefpodoxime proxetil, an ester prodrug of cefpodoxime, is an oral third-generation cephalosporin antibiotic that is used for the treatment of odontogenic infections such as periodontitis, pericoronitis, and osteitis of jaw. However, there are only a few studies on cephalosporin concentrations in human oral tissues. The present study therefore was undertaken to determine cefpodoxime concentrations in human oral tissues following oral administration of cefpodoxime proxetil. Cefpodoxime concentrations in human serum, gingiva, mandibular bone, and dental follicle following a single oral administration of 200- mg cefpodoxime proxetil were measured by a paper disk method. The mean peak concentrations in serum, gingiva, mandibular bone, and dental follicle occurred at the same time point, 3 hours post-dose, and were 3.07 ± 0.96 μg/mL, 1.16 ± 0.35 μg/g, 0.60 ± 0.27 μg/g, and 1.13 ± 0.34 μg/g, respectively. Mean cefpodoxime concentration ratios of gingiva / serum, mandibular bone / serum, and dental follicle / serum at the peak time were 0.40 ± 0.15, 0.20 ± 0.05, and 0.37 ± 0.03, respectively. Mean concentrations in gingiva, mandibular bone, and dental follicle at the peak time exceeded the minimum inhibitory concentration for 80% of clinically isolated strains of oral streptococci. Therefore, cefpodoxime proxetil may be a valuable antimicrobial agent for the treatment of odontogenic infection.

収録刊行物

  • IJOMS

    IJOMS 14 (2-3), 48-53, 2016

    日本大学松戸歯学部 口腔科学研究所

参考文献 (13)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ